Neal Shore, MD, FACS, offers clinical insights on optimizing patient selection and treatment sequencing in BCG-unresponsive NMIBC.
This is a video synopsis/summary of an Investigator Perspectives featuring Neal Shore, MD, FACS.
In concluding remarks on optimizing care, Shore reinforces that BCG remains standard of care for initial treatment of high-risk non–muscle invasive bladder cancer when available. In shortage settings, alternatives like dose-dense gemcitabine plus docetaxel should be considered. Across settings, enrolling patients in clinical trials is critical to advance the field.
For BCG-unresponsive patients, Shore recommends urologic oncologists consider checkpoint inhibitor immunotherapy if comfortable with managing potential immune-related adverse events. Collaboration with medical oncologists is advised given their expertise with these agents. Preventing recurrence and progression remains central to improving patient outcomes and burden of intensive management. Ultimately, Shore conveys excitement for preventing disease advancement in bladder cancer through new therapeutic strategies.
Video synopsis is AI generated and reviewed by Urology Times® editorial staff.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.